Evidence map›Paper›PMID 30167929›Full record

ReviewHeart failure reviews2019

Lanosteryl triterpenes from Protorhus longifolia as a cardioprotective agent: a mini review.

Nonhlakanipho F Sangweni, Phiwayinkosi V Dludla, Rebamang A Mosa, Abidemi P Kappo, Andy Opoku, Christo J F Muller, Rabia Johnson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Food & nutrition research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Nonhlakanipho F SangweniBiomedical Research and Innovation Platform (BRIP), South African Medical Research Council, Tygerberg, Cape Town, 7505, South Africa.
Phiwayinkosi V DludlaBiomedical Research and Innovation Platform (BRIP), South African Medical Research Council, Tygerberg, Cape Town, 7505, South Africa.
Rebamang A MosaDepartment of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa, 3886, South Africa.
Abidemi P KappoDepartment of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa, 3886, South Africa.
Andy OpokuDepartment of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa, 3886, South Africa.
Christo J F MullerBiomedical Research and Innovation Platform (BRIP), South African Medical Research Council, Tygerberg, Cape Town, 7505, South Africa.
Rabia JohnsonBiomedical Research and Innovation Platform (BRIP), South African Medical Research Council, Tygerberg, Cape Town, 7505, South Africa. rabia.johnson@mrc.ac.za.ORCID 0000-0002-6328-0789
South African Medical Research Council · ZAUniversity of Zululand · ZA

Funding

National Research Foundation for financial suppor, Thuthuka Grant UID107261South African Medical Research Councils' Research Strengthening and Capacity Development Funding Opportunity for Selected Universities Initiative 57009
6 · The paper itself

Abstract

The epidemic of cardiovascular diseases is a global phenomenon that is exaggerated by the growing prevalence of diabetes mellitus. Coronary artery disease and diabetic cardiomyopathy are the major cardiovascular complications responsible for exacerbated myocardial infarction in diabetic individuals. Increasing research has identified hyperglycemia and hyperlipidemia as key factors driving the augmentation of oxidative stress and a pro-inflammatory response that usually results in increased fibrosis and reduced cardiac efficiency. While current antidiabetic agents remain active in attenuating diabetes-associated complications, overtime, their efficacy proves limited in protecting the hearts of diabetic individuals. This has led to a considerable increase in the number of natural products that are screened for their antidiabetic and cardioprotective properties. These natural products may present essential ameliorative properties relevant to their use as a monotherapy or as an adjunct to current drug agents in combating diabetes and its associated cardiovascular complications. Recent findings have suggested that triterpenes isolated from Protorhus longifolia (Benrh.) Engl., a plant species endemic to Southern Africa, display strong antioxidant and antidiabetic properties that may potentially protect against diabetes-induced cardiovascular complications. Thus, in addition to discussing the pathophysiology associated with diabetes-induced cardiovascular injury, available evidence pertaining to the cardiovascular protective potential of lanosteryl triterpenes from Protorhus longifolia will be discussed.

Indexed as

AnacardiaceaeAnimalsCardiotonic AgentsCoronary Artery DiseaseDiabetes ComplicationsDiabetes MellitusDiabetic CardiomyopathiesDisease Models, AnimalHumansHypoglycemic AgentsHypolipidemic AgentsLanosterolPhytotherapyPlant ExtractsRatsCardiotonic AgentsHypoglycemic AgentsHypolipidemic AgentsLanosterolmethyl 3-hydroxylanosta-9,24-dien-21-oatePlant ExtractsCardiovascular diseasesDiabetesDiabetic cardiomyopathyProtorhus longifoliaTriterpenes

Identifiers

PMID30167929
OpenAlexW2889287253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.